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Abstract  
DNA repair pathways recognise and repair DNA damaged by exogenous and endogenous agents, in 
order to maintain genomic integrity. Defects in these pathways lead to replication errors, loss or 
rearrangement of genomic material and eventually cell death or carcinogenesis. The creation of 
diverse lymphocyte receptors to identify potential pathogens requires breaking and randomly re-
sorting gene segments coding for antigen receptors. Subsequent repair of the gene segments utilises 
ubiquitous DNA repair proteins. Individuals with defective repair pathways are increasingly 
recognised with immunodeficiency, many of whom are radiosensitive. The role of repair proteins in 
the development of adaptive immunity by VDJ recombination, antibody isotype class switching and 
affinity maturation by somatic hypermutation has become more clear over the last few years, partly 
by the identification of new genes involved in human disease. We describe mechanisms involved in 
the development of adaptive immunity relating to DNA repair, and describe the clinical 
consequences and treatment developments of primary immunodeficiency resulting from such 
defects. 
 
Radio-sensitive severe combined immunodeficiency, Ataxia-telangiectasia, Ataxia-
telangiectasia like disease, Nijmegen breakage syndrome, Artemis, DNA ligase 4, Cernunnos-
XLF, Autosomal recessive hyper IgM syndrome, common variable immunodeficiency, Bloom 
syndrome 
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Introduction 
DNA is constantly exposed to intra-cellular damaging events arising as intermediates in normal 
endogenous processes including DNA replication and meiosis and to extra-cellular agents including 
oxygen radicals or ionizing radiation (IR). Several pathways have evolved to recognise and repair 
damaged DNA to preserve genomic integrity. Defects in these pathways may allow replication 
errors, loss or rearrangement of DNA, mutagenesis, carcinogenesis and cell death. During T and B 
lymphocyte development, three specific mechanisms require repair to targeted DNA damage that 
has been introduced during development. This review will detail the molecular mechanisms, clinical 
presentation and treatment of human primary immunodeficiency disorders associated with defects 
in normal DNA damage recognition and repair. 
 
DNA Damage Sensing and Repair 
Maintenance of genomic integrity is critical to prevent cell death or tumour development. 
Chromosomal damage occurs secondary to exogenous damage from ionizing or ultraviolet 
radiation, chemicals, or from by-products of normal endogenous cellular physiological processes, 
including generation of free radicals, errors occurring during meiosis including nucleotide loss, or 
stalling of replication forks. Additionally, specialised cellular developmental programmes may 
generate DNA damage, such as that occurring during lymphocyte receptor development or 
generation of antibody diversity. Consequently, numerous inter-connected molecular mechanisms 
have evolved to prevent mutation accumulation, and maintain chromosomal structural integrity. 
Different repair pathways are required for the different types of DNA damage that may occur; 
whilst many utilise proteins and enzymes specific for that particular pathway, a number of proteins 
have multiple roles and function in combination to help sense or repair different forms of DNA 
damage. Bloom’s syndrome protein, an evolutionarily conserved RecQ helicase, has important roles 
in unwinding secondary DNA structures that inhibit replication fork progression in homologous 
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recombination. Interaction with proteins mutated in Fanconi’s anaemia, important for resolution of 
DNA cross-linking, has been demonstrated, as have interactions with ataxia-telangiectasia mutated 
(ATM) protein, an important protein which functions in DNA damage sensing, cell cycle 
checkpoints and DNA repair, and with MLH1, a protein involved in DNA mismatch repair.  
 
DNA-double strand breaks (DNA-DSB) are a serious form of DNA damage, which may generate 
harmful mutations and proliferation of damaged cells. Such damage elicits breakage sensing, signal 
transduction and effector function leading to cell cycle checkpoint arrest and/or apoptosis and can 
influence DNA repair. Recruitment of repair proteins to damaged sites involves those binding to the 
DNA break, and those binding to the surrounding chromatin, and occurs in a highly ordered 
sequence. The MRE11/RAD50/nibrin (MRN) complex is the initial sensor of DNA-DSB damage. 
Damaged DNA ends are tethered by the MRN complex, which aids the localised activation of 
ataxia telangiectasia mutated (ATM) protein, defective in ataxia telangiectasia, and the central 
component of the signal transduction pathway responding to DNA-DSB. Following ATM 
activation, several DNA repair and cell cycle checkpoint proteins, including H2AX, MDC1, and 
nibrin, are activated, leading to cell cycle arrest and DNA repair. H2AX is phosphorylated to γ-
H2AX and activates the cascade of repair protein re-localisation. MDC1 stabilizes the MRN 
complex at the site of the break to the adjacent chromatin, and co-ordinates assembly of other 
checkpoint and repair proteins to the surrounding chromatin, including 53BP1 and RNF168. Nibrin 
acts downstream of ATM by recruiting targets for ATM-mediated phosphorylation. 
 
Non Homologous End Joining Repair Pathway 
In response to DNA-DSB, cells have developed two general types of repair; homologous 
recombination (HR) and non homologous end joining (NHEJ). HR is generally limited to the late S 
phase and G2 phase of the cell cycle in mammalian cells, and uses information from a homologous 
 5
template to accurately repair breaks, when sister chromatids present readily available templates. 
NHEJ is the main DNA repair pathway that mediates the joining of broken regions of DNA that 
lack extensive homology and is the principle mechanism used in vertebrate cells during the G1 
phase cell cycle. Seven mammalian factors have now been identified as critical NHEJ components3. 
The DNA binding subunits Ku70 and Ku80 together with the DNA dependant protein kinase 
catalytic subunit (DNA-PKcs), form the DNA-PK holoenzyme, which is involved early in the 
recognition of DNA-DSB. Activated DNA-PK holoenzyme recruits other NHEJ proteins including 
artemis, XRCC4, DNA ligase 4 as well as DNA polymerase µ (Polµ) to the site of DNA damage 
(Figure 1). After phosphorylation by DNA-PKcs, the endonuclease artemis resolves complex DNA 
ends such as the heterologous loop and stem-loop DNA structures that contain single stranded DNA 
adjacent to double stranded DNA. Polµ is associated with both the KU heterodimer, and DNA 
ligase 4 and may have a role in gap filling during NHEJ, but is not critical for ligation. DNA ligase 
4, XRCC4 and Cernunnos-XRCC4-like factor (Cernunnos-XLF)4,5 are also required for the ligation 
reaction that rejoins the DNA-DSB. 
 
DNA Mismatch Repair 
Mismatch repair (MMR) corrects DNA mismatches generated during DNA replication so 
preventing mutations from becoming permanent in dividing cells.  Nucleotide mis-incorporation 
generates DNA base-base mismatches during DNA synthesis at a variable rate depending on many 
factors, including the specific DNA polymerases. The DNA MMR pathway is highly conserved, 
and specific primarily for base-base mismatches and insertion/deletion mispairs generated during 
DNA replication and recombination. A number of human MMR proteins have been identified based 
on homology to the E. coli mismatch repair proteins. Human MSH2 forms a heterodimer with 
MSH6 or hMSH3 to form MutSα or human MutSβ respectively, both of which are ATPases that 
play a critical role in mismatch recognition and initiation of repair. MutSα preferentially recognises 
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base to base mismatches and small nucleotide insertion-deletion mis-pairs of one or two 
nucleotides, while MutSβ preferentially recognises larger insertion/deletion mis-pairs.  Four human 
MutLhomologs (MLH1,MLH3, PMS1, PMS2) have been identified. MLH1 forms a heterodimer 
with PMS2, PMS1 or MLH3 to form MutLα, MutLβ or MutLγ respectively. Mutlα is required for 
mismatch repair by resolving the four-stranded DNA structures that form during HR in meiosis 
(DNA Holliday junctions). Heterodimers of Msh5 and Msh4 are postulated to form a ‘‘sliding 
clamp’’ on DNA and serve as scaffolding for the recombination machinery including the DNA 
repair proteins Mlh1 and PMS2. MutLγ plays a role in meiosis: no specific biological role has been 
identified for MutLβ. MutLα regulates termination of mismatch-provoked excision. Other enzymes 
involved in mismatch repair include proliferating cellular nuclear antigen (PCNA), DNA 
polymerase δ (Polδ) and DNA ligase 1.  PCNA interacts with MSH2 and MLH1 and is thought to 
play roles in the initiation and DNA re-synthesis steps of mismatch repair.  PCNA also interacts 
with MSH6 and MSH3 and may help localise MutSα and MutSβ to mis-pairs in newly replicated 
DNA. DNA re-synthesis and ligation is performed by DNA ligase 1. 
 
Role Of DNA Repair Proteins In Adaptive Immunity 
DNA Repair Proteins and Generation of Lymphocyte Antigen Receptors 
Effective immunity requires recognition of foreign antigens, requiring the generation of ≈1018 
genetically diverse cells, each with a unique receptor that recognises a unique antigen/MHC 
combination. In jawed vertebrates, these receptors are created by breaking, randomly resorting and 
joining DNA sequences coding for the antigen capture region of the receptor, by adapting the 
ubiquitous DNA repair mechanisms that maintain genome stability. 
 
Recombination is a site-specific event occurring at the T lymphocyte (cell) receptor (TCR) α, β, γ 
and δ chain loci, and the B lymphocyte (cell) receptor (BCR) immunoglobulin heavy (IgH), and 
 7
immunoglobulin κ or λ light (IgL) chain loci. Recombination occurs between component variable 
(V), junction (J), and for TCRβ, TCRδ, and BCR IgH loci, diversity (D) gene segments, with fused 
VJ or VDJ coding sequence subsequently joined to a constant region segment through RNA 
splicing. Two recombination activating gene proteins, (RAG1/2) introduce site-specific DNA-DSB 
at conserved non-coding DNA sequences adjacent to the points at which recombination occurs, 
known as recombination signal sequence (RSS) sites, either side of the segments to be rearranged, 
during the G1 phase of the cell cycle.  
 
After the introduction of DNA-DSB at the coding sequence/RSS junction, two types of DNA ends 
arise; coding sequence ends that reconstitute the Ig and TCR genes are generated as hairpin 
intermediates, whereas non-coding signal ends containing the motifs targeting site-specific cleavage 
are generated as blunt DS-DNA ends. ATM is not required for cleavage of coding joint hairpin 
intermediates (Ref. 1), but helps stabilise DNA-ends in the RAG post-synaptic cleavage complex, 
facilitating NHEJ repair of VDJ recombination associated breaks (Refs 2, 3, 4). ATM, nibrin, 
γH2AX and 53BPI are associated with RAG-induced DNA-DSB in developing lymphocytes and 
localise to DNA-DSB and the chromatin region surrounding the recombining loci (Refs 5, 6, 7, 8, 
9). By activating cell cycle checkpoint proteins, to enable monitoring of recombination 
intermediates, ATM may contribute to the efficiency of VDJ recombination. In the absence of 
ATM, lymphocytes with RAG-induced DNA-DSB may enter the S phase of cell cycle, leading to a 
reduction in productive VDJ recombination and an increased number of abnormal translocations 
involving Ig and TCR loci (Ref. 10).  
 
DNA-DSB are repaired using the NHEJ repair pathway (Table 1). The KU70/KU80 heterodimer 
binds DNA ends present at RAG1/2-generated coding ends and recruits DNA-PKcs that 
phosphorylates and activates artemis endonuclease activity to process the coding sequence hairpin 
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intermediates. Following cleavage, coding and signal ends are directly ligated by the XRCC4/DNA 
ligase 4/Cernunnos-XLF complex (Ref. 11) (Figure 1). Rejoining of signal ends does not require 
DNA-PKcs or artemis. VDJ recombination is not completely abolished if any of the 7 NHEJ 
proteins are impaired, as an alternative end-joining pathway exists, in which the frequent use of 
microhomology and excessive deletions are characteristic. RAG proteins play an essential role in 
the joining phase of V(D)J recombination, but allow a small degree of alternative NHEJ activity 
(Ref. 12).  
 
T and B lymphocyte receptor recombination occurs in the thymus and bone marrow respectively. 
Early lymphocyte progenitors undergo successive stages of lineage commitment, generating a 
functional lymphocyte receptor repertoire. Between critical developmental stages of VDJ re-
arrangement of the T lymphocyte β and α chain, and B lymphocyte IgH and IgL chain, the 
lymphocyte precursors undergo intense proliferation. During this phase, cells experience the normal 
replicative stress of proliferating cells, and in doing so, accumulate abnormal replication 
intermediates, normally resolved by Bloom syndrome protein.  
 
DNA Repair Proteins and Immunoglobulin Class Switch Recombination  
Maturation of the antibody repertoire is required to optimise antibody responses with high antigen 
affinity. Antibody maturation occurs in the germinal centres of secondary lymphoid organs in 
response to antigen and T-lymphocyte-driven activation; B lymphocytes vigorously proliferate, 
dividing every 6-8 hours and accumulating abnormal replication intermediates acquired during the 
normal replicative stress of proliferating cells, which are resolved by Bloom syndrome protein. 
Class switch recombination (CSR) is a somatic DNA arrangement process, which results in a switch 
in the IgH constant region of the BCR, expressed from the region encoded by Cµ to a downstream 
constant region such as that encoded by Cα, Cγ or Cε. Switch (S) regions lie in the J-C intron. DNA 
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recombination occurs between Sµ and the S region upstream of the C region for the particular 
antibody isotype, resulting in deletion of the intervening DNA. This results in the production of 
antibodies of different isotypes (IgG, IgA and IgE) with the same V(D)J specificity and therefore 
the same antigen affinity (Ref. 13). Activation-induced cytidine deaminase (AID), a B lymphocyte-
specific enzyme critical for CSR, induces DNA-DSB, to initiate CSR (Refs 14, 15). AID selectively 
deaminates cytosine (C) residues to uracil (U) in the switch (S) and variable regions (Ref. 16). 
Uracil DNA glycosylase removes uracil, producing an abasic site, which is cleaved by one of the 
base excision repair enzymes to create a DNA single strand break (-SSB) (Refs 17, 18). The MMR 
proteins MSH2-MSH6 recognise U at U:G mismatched bases, and create a further DNA-SSB (Ref. 
19). If a particular U is on the complementary strand to a previous DNA-SSB, a DNA-DSB results, 
enabling CSR to occur (Ref. 20) (Figure 2). PMS2, acting as a heterodimer with MHL1, converts 
AID/UNG –induced DNA-SSB into the DNA-DSB required for CSR by stabilizing the 
recombination intermediate (Refs 21, 22). MSH5 is also involved in CSR, and may have a specific 
role in facilitating CSR between Sµ and Sα (Ref. 23). 
A significant role for Bloom syndrome protein is unlikely during CSR (Ref. 24), although it does 
interact with MLH1 and MSH6 (Refs 21, 25, 26). CSR DNA-DSB repair is achieved mainly 
through NHEJ during the G1 phase of the cell-cycle (Ref. 27) although an alternative end-joining 
mechanism is used when there is impairment of NHEJ (Ref. 28). ATM is required for efficient 
CSR, although the exact function remains unclear. ATM is also associated with MMR factors, 
including MSH2, MSH6, MLH1 and PMS2 (Ref. 29). Additionally, nibrin, MRE11, γH2AX, and 
53BP1, foci of which can be detected at the DNA-DSB switch region during CSR, are 
phosphorylated by ATM (Refs 30, 31, 32, 33). One role of ATM may be to recruit or activate these 
factors, and organize the damaged DNA ends for subsequent repair steps, or arrest cell cycle 
progression until the repair is complete. ATM may have a more direct role in the end-processing 
step through phosphorylation of MRE11 or artemis that participate in NHEJ. Artemis is 
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downstream in the ATM signaling pathway for repair of a subset of radiation-induced DNA-DSB, 
but dispensable for ATM-dependent cell-cycle checkpoint arrest (Ref. 1), and appears dispensable 
for processing of DNA-DSB for efficient CSR (Ref. 34), although may be required for repair of the 
CSR-related chromosomal breaks at the Ig locus (Ref. 35), and for the resolution of a subset of 
breaks generated during CSR (Ref. 36). The altered pattern of CSR junctions in artemis-deficient 
patients also suggests that Artemis is required in the predominant NHEJ pathway during CSR (Ref. 
37). Deficiency in MRE11, nibrin, KU70/80 DNA-PKcs and DNA Ligase 4 appears to alter the 
balance between the predominantly used NHEJ and alternative end-joining mechanism in CSR 
DNA-DSB repair, suggesting that these proteins are also involved directly or indirectly in CSR 
(Ref. 38).  
 
Little is known about the proteins or mechanism involved in the alternative end-joining mechanism. 
Poly (ADP-ribose) polymerase 1 (PARP-1) is involved in many cellular responses including base 
excision repair (BER) and possibly HR (Ref. 39). It may be involved in the alternative end-joining 
pathway, with XRCC1 and DNA ligase 3 (Refs 40, 41, 42). DNA ligases 1 and 3 are required for 
microhomology-mediated end joining but it is unknown which is involved in alternative end-joining 
during CSR (Ref. 43). 
 
DNA Repair Proteins and Somatic Hypermutation 
Whilst CSR and somatic hypermutation (SHM) occur together in germinal centres, neither is a 
prerequisite for the other because IgM may be mutated in the absence of any such feature in IgG or 
IgA isotypes (Ref. 44). SHM introduces random mutations into the BCR variable region resulting in 
minor conformational changes, enabling positive selection of B lymphocytes carrying a BCR with 
high antigen affinity (Ref. 45). SHM is initiated by AID, by RNA editing of variable region C to U  
residues (Ref. 46). The MMR proteins MSH2-MSH6 recognise AID-induced U/G residues, and 
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recruit the exonuclease EXO1 and DNA polymerase η leading to G:C to T:A transversions (Ref. 
47). Whilst NHEJ is not employed in SHM, the MRN complex is involved in DNA cleavage at 
AID-induced abasic sites during SHM (Ref. 48), and nibrin has a role in regulating strand-biased 
repair (Ref. 37). Bloom syndrome protein does not seem to be involved in SHM (Ref. 49). 
 
Primary Immunodeficiency Syndromes Associated with Genetic Defects in DNA Repair 
Genes 
A growing number of genetic defects in the DNA-DSB and -MMR pathways have been identified 
in humans with primary immunodeficiency (PID), providing insight into the clinical phenotype of 
genomic instability on the immune system (Table 2). 
 
DNA-DSB Initiation Defects 
Recombination activating gene 1 and 2 Deficiency 
Whilst not part of the DNA repair pathway, RAG 1 and 2 initiate DNA-DSB, which is required for 
VDJ recombination to develop TCR and BCR (Ref. 50). RAG1/2 are lymphoid-specific 
endonucleases, which bind DNA at RSS/coding sequence junctions. Nonsense mutations in RAG1/2 
give rise to a T-B-NK+ severe combined immunodeficiency (SCID) phenotype with absent 
immunoglobulins. Patients usually present in early infancy with persistent viral respiratory or gut 
infection and growth failure, or Pneumocystis pneumonitis, as with other forms of SCID. Missense 
mutations give rise to ‘leaky’ SCID, or Omenn syndrome (Ref. 51). Infants may present with 
lymphadenopathy, hepatosplenomegaly, erythroderma, alopecia, agammaglobulinaemia apart from 
a raised IgE, T lymphocytosis, and absent B lymphocytes with accompanying respiratory and 
gastrointestinal symptoms and failure to thrive (Refs 52, 53). T lymphocytes are activated and show 
a restricted TCR variable  β chain (VB) repertoire (Ref. 54). Biopsies of affected skin demonstrate a 
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histopathological pattern consistent with graft versus host disease, although T lymphocytes are 
autologous.  
 
Additional clinical phenotypes are described. Normal immunoglobulin levels, specific antibody 
responses to infectious agents or vaccine antigens, production of autoantibodies, a predominance of 
γδ T lymphocytes and development of Epstein-Barr virus (EBV)-associated lymphoproliferation 
have been described in some patients (Refs 55, 56). T and B lymphocytopenia, 
hypogammaglobulinaemia, recurrent viral infection, EBV-associated lymphoma, and extensive 
granulomatous lesions, associated with compound heterozygous mutations in RAG 1 and 2 are also 
documented (Ref. 57). 
 
DNA-DSB Damage Sensing and Cell Cycle Arrest Defects 
Ataxia Telangiectasia 
Ataxia telangiectasia (A-T) is a rare systemic autosomal recessive disorder caused by mutations in 
ATM (Ref. 58), manifest by progressive cerebellar ataxia, oculocutaneous telangiectasia, gonadal 
sterility, post-natal growth retardation and a high incidence of predominantly lymphoid tumours. 
Patients normally present with cerebellar ataxia before telangiectasia appear. Recurrent sino-
pulmonary infection can be a presenting feature and may be associated with a raised IgM and low 
or absent IgG (Ref. 59). Sinopulmonary infection combined with recurrent aspiration, can lead to 
chronic lung disease (Ref. 60). The incidence of infections is variable and correlates with the 
presence of two null mutations in ATM (Ref. 61). Immunological responses to bacterial antigens are 
generally reduced, particularly to polysaccharide antigen (Ref. 62). Lymphocytic interstitial 
pneumonitis has also been described (Ref. 63). Median survival is 22 years (Ref. 64).  
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Thymic output, is reduced, and there is restricted TCRVB repertoire, marked by oligoclonal 
expansions (Ref. 65). Chromosomal inversions and translocations, particularly chromosome 7:14 
translocations are seen in A-T. B lymphocyte repertoire is also restricted and skewed by diffuse 
oligoclonal expansions with normal VDJ joints. B lymphocytes from A-T patients have an intrinsic 
defect in maturation from IgM to other classes, due to a defect in CSR from Cµ to the most distant 
loci, reflecting the requirement of ATM for efficient recombination between immunoglobulin 
switch regions (Ref. 66).  
 
Nijmegen Breakage syndrome 
Nijmegen breakage syndrome (NBS) has characteristic facial appearances with receding forehead, 
receding mandible and prominent midface (‘bird-like’ facies) (Ref. 67). Additional features include 
epicanthic folds, large ears and sparse hair with microcephaly and mild mental retardation. Patients 
are prone to sino-pulmonary infection and are susceptible to B lymphocyte lineage lymphomas. 
Cellular immunity is consistently impaired in NBS patients; lymphopenia is common with reduced 
proportions of CD3 and CD4 T lymphocytes (Ref. 68). Agammaglobulinaemia is reported in about 
a third of NBS patients whilst in others the humoral immune deficiency is more variable.  
Deficiencies of IgA or IgG4 alone or in combination are common (Ref. 69). About 10% of patients 
have normal immunoglobulins. The immunodeficiency may result from reduced fidelity of VDJ 
recombination, as nibrin is involved with ATM in inducing cell cycle arrest during this process 
(Ref. 70). Frequency of VDJ recombination in NBS patients is normal however with normal IgH 
rearrangement. The deficiency of serum IgG and IgA with normal or raised IgM is likely due to 
impaired CSR (Refs 71, 72).  
 
Chromosomal inversions and translocations, particularly chromosome 7:14 translocations are 
characteristic of NBS (figure 3). NBS cells are sensitive to DNA cross-linking agents such as 
mitomycin C and diepoxybutane (DEB), in addition to IR. Patients with certain NBS1 mutations 
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have features similar to FA (Refs 73, 74), although immunodeficiency is more pronounced, 
presumably because of the role of nibrin in VDJ recombination and CSR. 
 
Ataxia Telangiectasia-Like Disorder 
Ataxia telangiectasia like disorder is extremely rare with only 19 patients reported worldwide with 
mutations in MRE11A (Refs 75, 76, 77, 78, 79). Clinical features are similar to those in patients 
with A-T with progressive cerebellar ataxia that is of later onset and slower progression than of 
those with A-T (Ref. 80). Telangiectasia are absent.  Immunoglobulin levels are normal although 
deficiency in antigen specific antibodies has been reported, particularly to pneumococcal 
polysaccharide antigen (Ref. 81). Lymphoid tumours have not been reported, although two siblings 
with a novel mutation developed poorly differentiated lung adenocarcinoma (Ref. 79). Some 
patients are microcephalic, and although intelligence is generally normal, psychomotor retardation 
has been reported (Ref. 79). MRE11A encodes for a protein that associates in the MRN complex, 
and patients have features overlapping with both A-T and NBS. The absence of reported recurrent 
pulmonary infection due to immunodeficiency may reflect clinical variability as seen in A-T, or the 
type of mutation present, the majority of which are homozygous missense mutations. Given the role 
of MRE11 in CSR, it would appear logical that a degree of hypogammaglobulinaemia is likely in 
some patients at least. Defective CSR has been reported with reduced switching from Sµ-Sα, and 
an increased usage of microhomology at switch junctions (Ref. 81). 
 
RAD50 Deficiency 
One patient has been described with NBS-like features, in whom compound heterozygous 
mutations in RAD50, one of the components of the MRN complex, were found. The clinical 
features comprised intra-uterine growth retardation with microcephaly, poor post-natal growth and 
‘bird-like’ facies. Speech delay was also noted; ongoing follow up has demonstrated moderate 
psychomotor retardation, with mild spasticity and a non-progressive ataxic gait. She developed 
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multiple cutaneous pigmented naevi and hypopigmented areas. There was no history of excessive 
infections. Lymphocyte numbers, proliferations to mitogens and immunoglobulin levels were 
normal. However, chromosomal instability with 7:14 translocations was noted and there was 
radiosensitivity (Ref. 82). At last follow up aged 23 years of age she had not developed 
myelodysplasia or lymphoid malignancy. In this individual, one mutation created a premature stop 
codon, the other led to an abnormally large polypeptide (Ref. 83). No information is available on 
the use of microhomology at V-J junctions. One report implicates RAD50 in fidelity of end-joining 
of VDJ signal join substrates (Ref. 84). It is of interest that the phenotype of RAD50 deficiency 
more closely resembles that of NBS than A-T, unlike MRE11 deficiency. Whilst immunodeficiency 
was not reported in this patient, given the function of RAD50 in the MRN complex in TCR and 
BCR formation and CSR, it seems likely that immunodeficiency will be a feature of the expanded 
phenotype in other patients. 
 
Radiosensitivity, Immunodeficiency, Dysmorphic features and Learning difficulties (RIDDLE) 
Syndrome 
One caucasian patient has been described to date with Radiosensitivity, Immunodeficiency, 
Dysmorphic features and Learning difficulties (RIDDLE syndrome) (Ref. 85). He presented with 
mild facial dysmorphism, short stature, learning difficulties and mild motor abnormalities. There 
were no oculocutaneous telangiectasia. By 1 year of age he had low serum IgG levels, but normal 
IgM and IgA. T and B lymphocyte numbers were normal. From the age of 3 years he was treated 
with replacement immunoglobulin and has remained well. Biallelic mutations in RNF168, coding 
for a ubiquitin ligase, have subsequently been reported (Ref. 86). B lymphocytes from the patient 
demonstrated increased use of microhomology across the Sµ-Sα and Sα-Sγ3 switch regions with a 
reduced frequency of mutations and insertions, findings similar, although less severe, to those found 
in DNA ligase 4 deficiency, and suggestive of abnormal CSR. SHM was normal. Fibroblasts 
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exhibited moderately increased sensitivity to ionising radiation, and failed to localize 53BP1 to 
damaged chromatin. RNF168 plays a role in organising chromatin to facilitate long-range NHEJ, 
essential for CSR, but not VDJ recombination, likely explaining normal cellular immunity in the 
patient (Refs 87, 88, 89). 
 
DNA-DSB Recognition Defects 
DNA-PK Deficiency 
One Turkish patient, of consanguineous parents, has been described to date with a homozygous 3-
nucleotide deletion and homozygous missense mutation in PRKDC (Ref. 90). The patient presented 
at 5 months of age with classical symptoms of recurrent oral candidiasis and lower respiratory tract 
infections, and a T-B-NK+ SCID phenotype. No microcephaly or developmental delay was present. 
The arrest in B lymphocyte precursor differentiation was consistent with a defect in VDJ 
recombination. Fibroblasts were sensitive to IR, with a DNA-DSB repair defect comparable with 
that seen in artemis-deficient cells. Coding joints showed long stretches of palindromic nucleotides, 
and an end-joining assay demonstrated increased microhomology use, similar to that seen in 
artemis-deficient cells.  
 
DNA-DSB Processing Defects 
Artemis Deficiency 
Artemis is critical for VDJ recombination; null mutations in DCLRE1C give rise to a T-B-NK+ 
SCID phenotype (Ref. 91), originally described in Athabascan-speaking native Americans (Ref. 
92). Fibroblasts from these patients exhibited increased cellular sensitivity to IR (radiosensitive, 
RS-SCID) (Ref. 93), but the clinical presentation is otherwise identical to RAG-deficient SCID. 
Omenn syndrome has been described due to hypomorphic mutations in DCLRE1C (Ref. 94), 
analogous to the clinical presentation due to hypomorphic RAG mutations. Other patients have 
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presented with a progressive combined immunodeficiency (CID) from later infancy, characterised 
by recurrent sinopulmonary or gastrointestinal infection, T and B lymphopenia, 
hypogammaglobulinaemia, and autoimmune cytopenias (Refs 95, 96). Some show susceptibility to 
EBV-associated B lymphomas (Ref. 95). Chromosome 7:14 inversions and translocations have 
been described in these patients. No microcephaly has been noted.  
 
 
DNA-DSB Resolution Defects  
DNA Ligase IV Deficiency 
DNA ligase 4 deficiency was first described in a patient who was clinically and developmentally 
normal until T lymphocyte acute lymphoblastic leukaemia developed. Disproportionately severe 
cytopenia followed treatment, and standard chemotherapy consolidation therapy was omitted. He 
developed an extreme reaction to radiotherapy, including marked and prolonged cytopenia, severe 
desquamation, and died from radiation-induced encephalopathy (Ref. 97). Subsequently, a number 
of additional DNA ligase 4-deficient patients have been described. Six had microcephaly, 
developmental delay, growth failure, lymphopenia, hypogammaglobulinaemia, and recurrent 
infection (Refs 98, 99). Marrow hypoplasia was a feature in some of these patients. RS-SCID with 
microcephaly and growth delay has also been reported (Ref. 100, 101). Four patients with 
microcephaly and a combined immunodeficiency phenotype have been reported, of whom two 
developed an EBV-associated diffuse large cell non-Hodgkin lymphoma, and one developed T 
lymphocyte acute lymphoblastic leukaemia (Refs 102, 103, 104, 105). One patient presented with 
features consistent with Omenn syndrome (Ref. 105). Other clinical features include 
photosensitivity and psoriatic-like lesions (Ref. 98). 
 
Moderate impairment of VDJ recombination is observed in LIG4-deficient fibroblast VDJ 
recombination assays: an almost normal frequency of coding and signal joint formation is observed, 
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but fidelity of both coding and signal joint formation is impaired, with marked infidelity in coding 
end rejoining (Refs 98, 101). The in vitro findings are less severe than the clinical 
immunodeficiency, suggesting that DNA ligase 4 is required during lymphocyte development at 
stages beyond VDJ recombination, possibly to repair DNA damage that may occur during 
lymphocyte proliferation. Similar observations have been identified in patients with hypomorphic 
DCLRE1C mutations (Ref. 96). Patients with LIG4 mutations also have altered resolution of CSR 
junctions, with greater use of microhomology at Sµ-Sα junctions (Ref. 38). 
 
Cernunnos-XLF Deficiency 
Deficiency of Cernunnos-XLF has been described in 8 patients to date (Refs 106, 107): the first 2 
presented with T and B lymphocytopenia, with a normal number of NK cells (Ref. 108). 
Subsequently, five patients with combined immunodeficiency (CID) have been described (Ref. 
106). All had a similar lymphocyte phenotype to the original kindred, but additionally had low IgA 
and IgG. Two had raised IgM, suggesting a role for Cernunnos-XLF in CSR. Some patients 
described were microcephalic with ‘bird-like’ dysmorphism, two exhibited autoimmune cytopenia, 
and all suffered from recurrent bacterial and opportunistic infection. Two demonstrated several 
chromosomal alterations, although chromosome 7:14 translocations were not described. 
Lymphomas have not been described to date. A further patient has been described, who had similar 
morphological features of microcephaly, small stature and ‘bird-like’ facies. He suffered recurrent 
respiratory infections, and demonstrated normal IgM, but low IgA and IgG levels and absent 
response to vaccine protein antigens. His lymphocyte phenotype was characteristic (Ref. 109). He 
developed pancytopenia with tri-lineage marrow dysplasia, and enteropathy, and underwent 
successful haematopoietic stem cell transplantation at 10 years of age, complicated by EBV-
associated post-transplant lymphoproliferative disease.  
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Other clinical abnormalities include bone malformations (low implantation of the thumb, 
hypoplasia of the middle phalanx of the fifth finger), nephroptosis and one patient demonstrated 
developmental delay, features that overlap with those described in DNA ligase 4 deficiency. 
 
In vitro coding and signal joint formation were reduced in patients compared to controls, with an 
increase in nucleotide loss in coding joins. The fidelity of signal joins was severely impaired in 
patient cells, with use of microhomology during joining (Ref. 106), features previously described in 
LIG4-deficient patients (Refs 97, 99). VDJ deficiency in these patients is less severe than in the 
artemis-deficient RS-SCID and probably accounts for the presence, albeit in low numbers, of T and 
B lymphocytes found in the patients. As in patients with LIG4 deficiency, the in vitro findings are 
less severe than the clinical immunodeficiency, suggesting that Cernunnos-XLF may also be 
required during lymphocyte development after VDJ recombination has occurred. Cernunnos-XLF 
may be important for cell replication-induced DNA-DSB repair (Ref. 110). 
 
Other Uncharacterised Disorders 
A number of genetically undefined disorders, with phenotypic and cellular features characteristic of 
NBS (Refs 111, 112, 113), or Omenn-like SCID (Ref. 114) but with no mutations in candidate 
genes, have been described implicating further DNA repair genes in human primary 
immunodeficiency. 
 
Class Switch Recombination and Somatic Hypermutation Defects 
Autosomal Recessive Hyper-IgM Syndromes 
Three autosomal receesive hyper-IgM syndromes have been described due to defects in DNA break 
and repair mechanisms, which lead to decreased or abolished isotype switching and impaired 
somatic hypermutation.  
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AID deficiency 
AID deficiency, an autosomal recessive disease due to mutations in AID, normally presents in early 
childhood with severe, recurrent infections, most commonly recurrent sino-pulmonary or 
gastrointestinal infections (Refs 115, 116). Despite this early presentation, many patients are not 
diagnosed and treated until the second or third decade of life (Ref. 117). Massive 
lymphadenopathy, with giant germinal centres on histological examination are characteristic. 
Immunological features include raised IgM and low or absent IgA and IgG. There is an increased 
incidence of organ-specific autoimmune disease in these patients, particularly diabetes mellitus, 
polyarthritis, autoimmune hepatitis and Crohn’s disease (Ref. 117).  
 
Patients with impaired CSR but normal SHM have mutations in the carboxy-terminal region of 
AID, and present with milder disease (Ref. 118), and a small subset may present with autosomal 
dominant disease (Ref. 119). 
 
UNG Deficiency 
Three patients have been described with a defect in uracil-DNA glycosylase (UNG). Clinical 
presentation was similar to those with AID deficiency including recurrent respiratory tract 
infections from early childhood, and lymphoid hyperplasia (Ref. 120). Raised IgM and profoundly 
decreased IgA and IgG serum levels were found, with depressed antigen-specific antibody 
responses. A skewed pattern of SHM was found with almost all mutations being transitions (G>A, 
C>T). 
 
PMS2 Deficiency 
PMS2 forms a heterodimer with MLH1 to form Mutα, important in mismatch repair. Defects have 
been described in 3 individuals (Ref. 22). In addition to raised serum IgM and decreased IgA and 
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IgG with recurrent infections, café au lait spots and malignancy including leukaemias, lymphomas, 
cerebral tumours and colorectal tumours are characteristic (Refs 121, 122). Increased levels of 
microhomology were found across the Sµ-Sα switch junctions. SHM may have been mildly 
reduced. 
 
MSH5 Deficiency 
MSH5 has been implicated in IgA deficiency and common variable immunodeficiency (Ref. 23). 
Increased microhomology at Sµ-Sα switch junctions was found in patients carrying disease-
associated MSH5 allelles, with fewer mutations than in controls. The precise mechanism by which 
defects in MSH5 contribute to the abnormalities observed in CSR has not been elucidated. 
 
Undefined Defects of Class Switch recombination and Somatic Hypermutation 
Further, as yet undescribed, gene defects give rise to a clinical picture of hyper IgM syndrome. 
Hyper IgM type 4 has been described in 15 patients with characteristic features of recurrent 
respiratory and gastrointestinal tract infection, lymphoid hyperplasia and autoimmune features (Ref. 
123). CSR was defective, but SHM normal. AID and UNG mutations were excluded in all patients.  
 
A further clinical entity consisting of increased radiosensitivity but normal checkpoint arrest and 
NHEJ, increased levels of microhomology across Sµ-Sα switch junctions and a skewed SHM 
toward transitions at G/C residues has been described in 5 patients (Ref. 124). All had recurrent 
respiratory infections: lymphoid hyperplasia and autoimmunity were also described. Raised IgM 
and decreased IgA and IgG levels were noted. A genetic defect has yet to be identified. A further 
group of patients has been described, in whom recurrent bacterial infection, autoimmunity and 
lymphadenopathy are observed, although the lymphadenopathy was less marked than in AID-
deficient patients. There was a lack of class-switched B lymphocytes in these patients, although 
 22
SHM was normal. There was no sensitivity to IR (Ref. 125). Defective CSR associated with growth 
hormone deficiency has been described in two patients in whom the molecular defect has yet to be 
discovered (Ref. 126, 127). 
 
Other Human Primary Immunodeficiency Syndromes Associated with DNA Repair Gene Defects 
DNA Ligase 1 
To date, one patient has been described with two compound missense mutations in LIGI (Refs 128, 
129). Clinical features, overlapping with those of Bloom syndrome and ataxia - telangiectasia, 
included intra-uterine and post-natal growth retardation, developmental delay with normal cognitive 
development, dysmorphism with elf-like features, and photosensitivity. Immunodeficiency 
manifested as recurrent middle ear and respiratory infections from age 2 years, with evolving IgA 
deficiency, relative hypogammaglobulinaemia of IgG and normal IgM. There was an evolving 
lymphocytopenia with poor proliferative response to mitogens. During teenage years the respiratory 
status deteriorated and secondary sexual characteristics did not develop. At the age of 17 years, 
patches of cutaneous venous dilatation appeared mainly on the limbs, and there was some bulbar 
conjunctival telangiectasia. Hepatosplenomegaly developed with associated neutropenia and 
increasing lymphopenia. A liver biopsy showed lymphocyte infiltration of the portal tract, 
suggesting lymphoma. The patient developed a severe cutaneous herpes zoster infection and died 
from pneumonia at the age of 19 years. No information on end-joining of VDJ substrates was 
available, or on the use of microhomology. An increase in the number of DNA-SSB and –DSB in 
newly replicated DNA molecules was seen in an immortalised fibroblast line, possibly because of 
the failure of dealing with damage at replication forks (Ref. 130). The cause of the 
immunodeficiency can only be conjectured, given the paucity of data. There is no evidence linking 
DNA ligase 1 with VDJ recombination (Ref. 131). DNA ligase I complexes with nibrin, and both 
co-localize at replication factories to repair DNA-DSB by homologous recombination at stalled 
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replication forks (Ref. 132), suggesting defects in DNA ligase I may be associated with failure to 
repair DNA damage during lymphocyte proliferation, rather than failure to complete NHEJ in TCR 
and BCR formation. The finding of low IgA and IgG, but normal IgM is tantalising, and further 
work needs to be done to investigate what role, if any, DNA ligase I has in CSR. 
 
Bloom Syndrome 
Bloom syndrome is an autosomal recessive disorder characterized by proportionate pre- and 
postnatal growth deficiency, photo-sensitive, telangiectatic, hypo- and hyperpigmented skin, 
predisposition to malignancy and chromosomal instability. There is an increased incidence of 
diabetes mellitus. Immunodeficiency, whilst common, is variable and generally not severe (Ref. 
133, 134), although life-threatening infection may occur (Ref. 135). Low concentrations of one or 
more immunoglobulin isotypes are most often found (Refs 133, 134, 136). Impaired T lymphocyte 
proliferation, diminished CD4+ T lymphocyte numbers and impaired function have been described 
in Bloom syndrome patients (Refs 133, 137). There is a characteristic increase in sister chromatid 
exchange seen on cytogenetic analysis (Figure 4). Bloom syndrome protein has no role in VDJ 
recombination (Ref. 138, 139), and has only a minor role, if any in CSR, although microhomology–
mediated end joining was observed at Sµ-Sγ3 switch regions, possibly implicating Blm in the 
resolution phase of CSR (Ref. 140). 
 
Fanconi Anaemia 
Fanconi anaemia (FA) is a clinically heterogenous autosomal recessive or X-linked disorder 
characterised by bone marrow failure, skeletal, renal, cardiac and gastrointestinal defects, 
hypopigmentation and predisposal to malignancy (Ref. 141). The majority of immunological 
problems relate to bone marrow failure, but a few patients present early with significant or 
prolonged infections, more consistent with immunodeficiency (Ref. 73). Whilst cells from patients 
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show hypersensitivity to agents causing DNA interstrand cross-links, a few also demonstrate 
sensitivity to IR (Ref. 142). Thirteen FA genes have been identified to date. Whilst most of the FA 
proteins form a core ubiquitin ligase complex, FAND2 is ubquitinated by this complex, and then 
co-localizes to chromatin with other DNA repair proteins including the MRN complex (Ref. 73). 
The FA proteins do not appear to have direct a role in lymphocyte receptor development or 
modification, and effects on immunity are more likely to be a result of inter-strand cross-links 
occurring during cellular development, resulting in bone marrow failure. 
 
Diagnosis of DNA Repair Defects 
The diagnosis of radiosensitivity is difficult, time consuming and confined to a few laboratories. An 
index of clinical suspicion is necessary to consider the diagnosis, and diagnostic clues may be 
gathered from the clinical phenotype (e.g. microcephaly or telangiectasia) and immunological 
profile (e.g lymphocytopenia, raised IgM) (Table 2). Cytogenetic analysis may give some clues to 
the underlying diagnosis by the finding of chromosome 7:14 translocations, seen in AT, NBS and 
other IR sensitivity disorders (Table 2) or an increase in sister chromatid exchanges in Bloom 
syndrome (Figure 4). Sensitivity to ionising radiation can also be demonstrated using a clonogenic 
survival assay in which fibroblasts are irradiated with increasing doses of radiation and the 
percentage survival of cells is assessed after a fixed period of time (usually 3 weeks) (Ref. 96). A 
similar method is to subject cells to increasing doses of radiation and subsequently stain for γH2AX 
foci which are present at the site of DNA-DSB but disappear over time as the damage is repaired 
(Ref. 1): persistence of such foci is indicative of impaired repair mechanisms (Figure 5A). Different 
genetic causes give slightly different results, as in artemis-deficient cells, most cells show normal 
repair, with a small subset showing impairment, whereas DNA ligase 4-deficient cells show a 
greater degree of impairment to damage repair (Figure 5B).  
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Treatment of Primary Immunodeficiency Associated With DNA Repair Disorders 
Treatment for DNA-repair deficient primary immunodeficiencies depends on the clinical 
presentation, and is generally the same as for similar disorders due to other underlying molecular 
defects. Patients with B lymphocyte deficiency can be treated with prophylactic antibiotics and 
immunoglobulin replacement therapy. However patients with severe T lymphocyte deficiency 
require more aggressive therapy and haematopoietic stem cell transplantation may be indicated, 
particularly for children with recurrent infection and failure to thrive, and those at risk of 
developing malignancy. Because of the risk of generalised chromosome damage with the use of 
radiotherapy, this should be omitted from conditioning regimens. The use of reduced intensity 
chemotherapy conditioning appears to favour a successful outcome (Refs 69, 75, 143, 144). 
Modified chemotherapy regimens for the treatment of lymphoid malignancy are needed due to the 
high level of toxicity using conventional regimens (Ref. 145); radiotherapy should be avoided or 
restricted. The incidence of secondary malignancies is more frequent in these patients so careful 
follow up is required. Gene therapy maybe an alternative treatment for some conditions, although 
clinical trials are not yet in progress (Ref. 146). One novel approach to treatment currently in 
development is the use of antisense oligonucleotides to correct splicing, frameshift and missense 
mutations and thus convert absent or unstable protein to partially or fully functional protein (Ref. 
147), or the use of ribosomal readthrough agents to overcome premature termination codons, and 
enable some normal protein expression (Ref. 148). 
 
Polymorphisms in DNA Repair Genes 
Increasingly, non-disease associated polymorphisms are being found to exert subtle effects. A 
number of polymorphisms in different DNA repair genes have been associated with an increased 
risk of a number of different malignancies (Refs 149, 150) or increased sensitivity to radiotherapy 
Refs 151, 152). Polymorphisms in LIG4, in combination with a disease-causing mutation lead to a 
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more severe clinical phenotype than the mutation alone (Ref. 153). Counter-intuitively, some 
polymorphisms may also have a protective affect against developing malignancy (Ref. 154). 
 
Outstanding Questions 
Much has been learnt about the molecular mechanisms of lymphocyte receptor formation, 
immunoglobulin isotype switching and the affinity maturation from the careful study of human 
primary immunodeficiencies. Conversely, an understanding of the mechanisms has aided discovery 
of novel genetic immune defects in patients. Much has yet to be discovered however. The 
identification of more patients with extremely rare diseases such as Ligase I deficiency, RAD50 
deficiency, RIDDLE syndrome and PMS2 deficiency will expand the clinical phenotype, and give 
greater understanding of the role these proteins play in immune development. Key proteins in the 
DNA-DSB repair pathway, such as XRCC4, known to cause immunodeficiency in animal models, 
have yet to be linked to human disease. It is likely that careful study of milder antibody deficiencies 
will reveal further defects in MMR proteins responsible for SHM and antibody affinity maturation. 
An appreciation of the role that these defects play in immunodeficiency and in the wider biological 
processes of other cells is likely to lead to improved, more targeted treatments for these patients. As 
our understanding of how genetic haplotypes and SNP can influence disease risk, and response to 
treatment, progresses, tailored therapies are likely to become available for specific patient groups. 
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FURTHER READING, RESOURCES AND CONTACTS 
Primary Immunodeficiency Association website 
http://www.pia.org.uk 
Ataxia Telangiectasia Society 
http://www.atsociety.org.uk 
 
These patient organisations provide a useful point of contact for affected individuals. 
 
Specific diseases at the Online Mendelian Inheritance in Man (OMIM) website 
www.ncbi.nlm.nih.gov/omim 
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FIGURE LEGENDS 
Figure 1 
VDJ Recombination. 
A. DNA is uncoiled at transcription factories within the cell, where the associated 
recombination and repair proteins co-localise. 
B. The lymphoid specific recombinase activating gene 1 and 2 (RAG1/2) proteins 
recognise and bind the recombination signal sequences (RSS) that flank the VDJ gene 
segments, and introduce site-specific DNA-DSB through their endonuclease action.  
C. The phosphorylated blunt signal ends and the covalently sealed hairpin intermediate of 
the coding end are held together by the RAG complex. 
D. The MRN complex binds the broken DNA ends and activates ATM which initiates cell 
cycle arrest and attraction of the repair proteins. H2AX, 53BP1 and RNF168, with other 
proteins stabilise the damaged chromatin. 
E. i. Ku70/Ku80 heterodimer binds the coding ends and recruits DNA-PKcs and Artemis, 
which is required to open the hairpin intermediates. The covalently sealed hairpin 
intermediate is randomly nicked by the DNA-Pkcs/Artemis complex, which generates a 
single stranded break with 3’ or 5’ overhangs. ii. XRCC4, DNA ligase 4 and Cernunnos-
XLF (C-XLF) co-associate and are recruited to the ends. The signal ends are directly 
ligated by the XRCC4/DNA-LIG4/C-XLF complex. The opened hairpin intermediate is 
modified by polymerases, exonucleases and the lymphoid-specific terminal 
deoxynucleotidyl transferase (TdT), before iii. being repaired and ligated by the 
XRCC4/DNA-LIG4/C-XLF complex. (Reproduced with permission of Paediatric HSCT 
unit, Newcastle General Hospital) 
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Figure 2 
Class Switch Recombination (CSR) between Cµ and Cγ1 
A i-iii. Activation-induced cytidine deaminase (AID) selectively targets cytosine bases in the IgH 
constant region Cµ and Cγ1 switch regions in the B lymphocyte receptor gene. Cytosine residues are 
de-aminated to uracil. 
 
B i-iii. Uracil DNA glycosylase removes uracil, producing an abasic site, which is cleaved by one 
of the base excision repair enzymes to create a DNA single strand break. The mis-match repair 
proteins MSH2-MSH6 also recognise U at U:G mismatched bases, and create a further DNA- single 
strand break, resulting in a DNA-double strand break. 
 
C i. DNA-double strand break repair is achieved mainly through non-homologous end joining. 
ATM is required for the repair and may recruit or activate 53BP1, γH2AX and RNF168 which are 
likely to be involved at the synapsis. ATM may also phosphorylate artemis, required to repair a 
subset of DNA-double strand breaks, and organize the damaged DNA ends for subsequent repair 
steps, or arrest cell cycle progression until the repair is complete.  
ii. Nibrin, MRE11, and RAD50 are phosphorylated by ATM and may be required to activate ATM 
in CSR. MRE11, nibrin, KU70/80 DNA-Pkcs, XRCC4 and DNA Ligase 4 are likely to be involved 
in the final repair, as is Cernunnos-XLF.  
 
Figure 3. Karyotype from a patient with Nijmegen breakage syndrome showing (A) Chromosome 
t(7;14) re-arrangement (arrows), (B) chromosomal breakage following exposure to 50 centiGray 
ionizing radiation, (C) multiradial formation (arrow) after 72-h culture following exposure to 
Mitomycin C at 0.32 microgram/ml for 60 min, (D) chromosome breakage (arrow) following 
lymphocyte culture with DEB for 72 h (Reproduced with permission of Paediatric HSCT unit, 
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Newcastle General Hospital). 
 
Figure 4. Karyotype from a patient with Bloom syndrome showing (A) a symmetrical quadridradial 
(arrow), and (B) a large increase in numbers of sister chromatid exchanges from normal (arrows) 
(Reproduced with permission of Paediatric HSCT unit, Newcastle General Hospital). 
 
Figure 5. (A) γ-H2AX measurement in fibroblasts. Following IR, there is an increase over 
background in γ-H2AX foci at 0.25 hours in wild-type and artemis-deficient cell lines. By 72 hours, 
the wild-type fibroblasts have returned to normal, but the artemis-deficient fibroblasts still manifest 
γ-H2AX foci, consistent with defective DNA-DSB repair. (B) Serial measurements of γ-H2AX foci 
in wild-type, Cernunnos-XLF-deficient and Artemis-deficient fibroblasts. γ-H2AX foci disappear in 
the normal cells as DNA-DSB are repaired. Cernunnos-XLF-deficient cells show a repair defect 
that is observable at 2 hours after IR and remains up to 72 hours which indicates a DSB repair 
defect that impacts upon all NHEJ. The Artemis-deficient fibroblasts are completely normal at 2 
hours after IR, but shows little further repair beyond 24 hours, indicating a subset of breaks that 
remain un-repaired (approximately 10% of DNA-DSB). (Images courtesy of PA Jeggo). 
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Table 1. Proteins in the Non-homologous End Joining DNA Double Strand Break Repair Pathway 
 
 
Protein Function Human Disease Animal Model 
Ku 70 Associates with Ku80 to form 
a heterodimer which binds to 
both ends of broken DNA, 
promoting end-alignment of 
the two DNA ends and 
recruits and activates DNA-
PKcs. May act as a scaffold 
for subsequent assembly of 
NHEJ proteins. 
 
Not described Murine SCID 
Ku 80 Associates with Ku70 to form 
a heterodimer which binds to 
both ends of broken DNA, 
promoting end-alignment of 
the two DNA ends and 
recruits and activates DNA-
PKcs. May act as a scaffold 
for subsequent assembly of 
NHEJ proteins. 
 
Not described Murine SCID 
DNA Protein Kinase 
catalytic subunit 
DNA-PK molecules 
associated with each broken 
end of DNA form a synapse 
across the gap, interact with 
Artemis and stimulate 
processing of DNA ends. 
 
Radiosensitive SCID Canine, equine, murine 
SCID 
Artemis DNA-PKcs dependent 
endonuclease activity 
towards DNA DS-SS 
transitions and DNA 
hairpin intermediates. 
 
Radiosensitive SCID, 
combined 
immunodeficiency, 
lymphoma predisposition 
Murine SCID 
DNA ligase 4 Ligation of blunt DNA ends, 
compatible DNA overhangs 
and incompatible short DNA 
overhangs. Forms a complex 
with XRCC4 and C-XLF and 
promotes DNA binding of 
these proteins. 
 
Radiosensitive SCID, 
combined 
immunodeficiency, 
lymphoma and leukaemia 
predisposition 
Murine immunodeficiency 
and growth retardation with 
hypomorphic mutation, 
embryonic lethal knockout 
models 
XRCC4 Interacts with Ku and DNA 
to form a scaffold. Forms a 
complex with Ligase 4 and 
C-XLF 
 
Not described Embryonic lethal knockout 
models 
Cernunnos-XLF Part of the Ligase 4/XRCC4 
complex with enzymatic 
Radiosensitive combined 
immunodeficiency 
Radiosensitivity, modest 
lymphocytopenia, raised 
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activity  
 
IgM 
Pol λ Alignment-based gap 
filling of DNA breaks 
Not described Murine hydrocephalus, situs 
inversus, chronic sinusitis, 
and infertility 
 
Pol µ Alignment-based gap filling 
of DNA breaks 
 
Not described Murine model – B 
lymphocytopenia with 
impaired κ light chain gene 
rearrangement 
 
TdT Addition of random, 
nongermline encoded 
sequence to broken 
DNA ends DNA before 
joining during repair 
of intermediates in 
V(D)J 
Recombination. 
Not described Murine model - 
greater efficiency in 
positive selection of 
thymocytes. 
 
Pol λ, DNA polymerase λ:, Pol µ, DNA polymerase µ: TdT, terminal deoxynucleotidyl transferase 
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